Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gil Leibowitz

Showing results (31-40 of 69) with videos related to

Pageof 7
Sort By:
Diabetes Care|February 9, 2013
Decreased serum concentrations of 25-hydroxycholecalciferol are associated with increased risk of progression to impaired fasting glucose and diabetesAnat Tsur, Becca S Feldman, Ilan Feldhammer, et al.
Cancers|December 24, 2021
The Autophagy Inhibitor Chloroquine, Alone or in Combination with mTOR Inhibitors, Displays Anti-Tumor Effects in In Vitro and In Vivo Lung Carcinoid ModelsAdi Knigin, Shani Avniel-Polak, Gil Leibowitz, et al.
Current Medical Research and Opinion|April 5, 2007
In-hospital treatment of hyperglycemia: effects of intensified subcutaneous insulin treatmentHila Elinav, Zemira Wolf, Auryan Szalat, et al.
Plos One|October 26, 2016
Upregulation of Mitochondrial Content in Cytochrome c Oxidase Deficient FibroblastsAviram Kogot-Levin, Ann Saada, Gil Leibowitz, et al.
Diabetes|January 1, 2013
Stimulation of autophagy improves endoplasmic reticulum stress-induced diabetesEtty Bachar-Wikstrom, Jakob D Wikstrom, Yafa Ariav, et al.
JCI Insight|May 4, 2023
Time-dependent effects of endogenous hyperglucagonemia on glucose homeostasis and hepatic glucagon actionCamila Lubaczeuski, Nadejda Bozadjieva-Kramer, Ruy A Louzada, et al.
Cell Reports|May 10, 2025
Beta cells intrinsically sense and limit their secretory activity via mTORC1-RhoA signalingSaar Krell, Amit Hamburg, Ofer Gover, et al.
Cardiovascular Diabetology|November 7, 2025
Neurodegeneration onset with glucagon-like peptide-1 receptor agonists in people with type 2 diabetes: a real-world multinational cohort studyMeir Schechter, Alisa Fishkin, Ofri Mosenzon, et al.
Diabetes|November 25, 2005
Psammomys obesus, a model for environment-gene interactions in type 2 diabetesNurit Kaiser, Rafael Nesher, Marc Y Donath, et al.
Diabetes/Metabolism Research and Reviews|July 23, 2025
Kidney Outcomes With Glucagon-Like Peptide-1 Receptor Agonists Versus Other Glucose-Lowering Agents in People With Type 2 Diabetes: A Systematic Review and Meta-Analysis of Real-World DataAlisa Fishkin, Aliza Rozenberg, Meir Schechter, et al.
Pageof 7

Showing results (31-40 of 69) with videos related to

Sort By:
Pageof 7
Diabetes Care|February 9, 2013
Decreased serum concentrations of 25-hydroxycholecalciferol are associated with increased risk of progression to impaired fasting glucose and diabetesAnat Tsur, Becca S Feldman, Ilan Feldhammer, et al.
Cancers|December 24, 2021
The Autophagy Inhibitor Chloroquine, Alone or in Combination with mTOR Inhibitors, Displays Anti-Tumor Effects in In Vitro and In Vivo Lung Carcinoid ModelsAdi Knigin, Shani Avniel-Polak, Gil Leibowitz, et al.
Current Medical Research and Opinion|April 5, 2007
In-hospital treatment of hyperglycemia: effects of intensified subcutaneous insulin treatmentHila Elinav, Zemira Wolf, Auryan Szalat, et al.
Plos One|October 26, 2016
Upregulation of Mitochondrial Content in Cytochrome c Oxidase Deficient FibroblastsAviram Kogot-Levin, Ann Saada, Gil Leibowitz, et al.
Diabetes|January 1, 2013
Stimulation of autophagy improves endoplasmic reticulum stress-induced diabetesEtty Bachar-Wikstrom, Jakob D Wikstrom, Yafa Ariav, et al.
JCI Insight|May 4, 2023
Time-dependent effects of endogenous hyperglucagonemia on glucose homeostasis and hepatic glucagon actionCamila Lubaczeuski, Nadejda Bozadjieva-Kramer, Ruy A Louzada, et al.
Cell Reports|May 10, 2025
Beta cells intrinsically sense and limit their secretory activity via mTORC1-RhoA signalingSaar Krell, Amit Hamburg, Ofer Gover, et al.
Cardiovascular Diabetology|November 7, 2025
Neurodegeneration onset with glucagon-like peptide-1 receptor agonists in people with type 2 diabetes: a real-world multinational cohort studyMeir Schechter, Alisa Fishkin, Ofri Mosenzon, et al.
Diabetes|November 25, 2005
Psammomys obesus, a model for environment-gene interactions in type 2 diabetesNurit Kaiser, Rafael Nesher, Marc Y Donath, et al.
Diabetes/Metabolism Research and Reviews|July 23, 2025
Kidney Outcomes With Glucagon-Like Peptide-1 Receptor Agonists Versus Other Glucose-Lowering Agents in People With Type 2 Diabetes: A Systematic Review and Meta-Analysis of Real-World DataAlisa Fishkin, Aliza Rozenberg, Meir Schechter, et al.
Pageof 7